Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00005522

Trial Description

start of 1:1-Block title

Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

This is a multicenter, randomized, double-blind, Placebo-controlled Phase 3 study to compare
the PFS of subjects with 131I-refractory DTC and radiographic evidence of disease
progression within the prior 12 months, treated with E7080 (lenvatinib) 24 mg by continuous
once daily (QD) oral dosing versus Placebo.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

[---]*

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00005522
  •   2014/02/05
  •   2011/03/10
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT01321554  (ClinicalTrials.gov)
  •   E7080-G000-303  (Eisai Inc.)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Thyroid Cancer
  •   C73 -  Malignant neoplasm of thyroid gland
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: lenvatinib 24 mg administered orally, once a day
  •   Drug: Placebo 24mg administered orally, once a day
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, caregiver, investigator/therapist, assessor
  •   [---]*
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- To compare the Progression-free Survival (PFS) of subjects with 131IRefractory differentiated thyroid cancer (DTC) with radiographic evidence of disease progression within the prior 12 months treated with lenvatinib versus Placebo.; time frame: Date of randomization to the date of disease progression (measured every 8 weeks) or death (whichever occurs first) as determined by blinded independent imaging review

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- To compare Overall Response Rate (ORR) (Complete and Partial Responses, CR and PR) of subjects treated with lenvatinib versus Placebo.; time frame: Date of randomization to the date of disease progression (measured every 8 weeks) or death

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   Argentina
  •   Australia
  •   Austria
  •   Belgium
  •   Brazil
  •   Canada
  •   Chile
  •   Czech Republic
  •   Denmark
  •   France
  •   Germany
  •   Italy
  •   Japan
  •   Korea, Republic of
  •   Poland
  •   Portugal
  •   Romania
  •   Russian Federation
  •   Spain
  •   Sweden
  •   Thailand
  •   United Kingdom
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
  •  
  •  
  •  
  •  
  •  
  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2011/05/31
  •   392
  •   [---]*
  •   [---]*
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

INCLUSION

1. Subjects must have histologically or cytologically confirmed diagnosis of one of the
following differentiated thyroid cancer (DTC) subtypes:

a. Papillary thyroid cancer (PTC) i. Follicular variant ii. Variants (including but
not limited to tall cell, columnar cell, cribriform-morular, solid, oxyphil,
Warthin's-like, trabecular, tumor with nodular fasciitis-like stroma, Hürthle cell
variant of papillary carcinoma, poorly differentiated) b. Follicular thyroid cancer
(FTC) i. Hürthle cell ii. Clear cell iii. Insular

2. Measurable disease meeting the following criteria and confirmed by central
radiographic review:

1. At least 1 lesion of ≥ 1.0 cm in the longest diameter for a non-lymph node or ≥
1.5 cm in the short-axis diameter for a lymph node which is serially measurable
according to RECIST 1.1 using computerized tomography/magnetic resonance imaging
(CT/MRI). If there is only one target lesion and it is a non-lymph node, it
should have a longest diameter of ≥ 1.5 cm

2. Lesions that have had external beam radiotherapy (EBRT) or loco-regional
therapies such as radiofrequency (RF) ablation must show evidence of progressive
disease based on RECIST 1.1 to be deemed a target lesion

3. Subjects must show evidence of disease progression within 12 months (an additional
month will be allowed to accommodate actual dates of performance of screening scans,
i.e., within ≤ 13 months) prior to signing informed consent, according to RECIST 1.1
assessed and confirmed by central radiographic review of CT and / or MRI scans

4. Subjects must be 131I-refractory / resistant as defined by at least one of the
following:

1. One or more measurable lesions that do not demonstrate iodine uptake on any
radioiodine scan

2. One or more measurable lesions that has progressed by RECIST 1.1 within 12
months of 131I therapy, despite demonstration of radioiodine avidity at the time
of that treatment by pre- or post-treatment scanning. These subjects must not
be eligible for possible curative surgery

3. Cumulative activity of 131I of > 600 mCi or 22 gigabequerels (GBq), with the
last dose administered at least 6 months prior to study entry

5. Subjects may have received 0 or 1 prior VEGF / VEGFR-targeted therapy ( for example
sorafenib, sunitinib, pazopanib, etc.)

6. Subjects with known brain metastases who have completed whole brain radiotherapy,
stereotactic radiosurgery or complete surgical resection, will be eligible if they
have remained clinically stable, asymptomatic and off of steroids for one month

7. Subjects must be receiving thyroxine suppression therapy and thyroid stimulating
hormone (TSH) should not be elevated (TSH should be ≤ 5.50 mcu/mL). When tolerated
by the subject, thyroxine dose should be changed to achieve TSH suppression (TSH <
0.50 mcu/mL) and this dose can be changed concurrently upon starting lenvatinib

8. All chemotherapy or radiation-related toxicities must have resolved to < Grade 2
severity, except alopecia and infertility

9. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of
0 − 2

10. Adequately controlled blood pressure with or without antihypertensive medications,
defined as BP < 150/90 mmHg at screening and no change in antihypertensive
medications within 1 week prior to Cycle 1 Day 1

11. Adequate renal function defined as calculated creatinine clearance ≥ 30 mL/min per
the Cockcroft and Gault formula

12. Adequate bone marrow function:

1. Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥ 1.5 × 103/μL)

2. Platelets ≥ 100,000/mm3 (≥ 100 × 109/L)

3. Hemoglobin ≥ 9.0 g/dL

13. Adequate blood coagulation function as evidenced by an International Normalized Ratio
(INR) ≤ 1.5

14. Adequate liver function:

1. Bilirubin ≤ 1.5 × the upper limit of normal (ULN) except for unconjugated
hyperbilirubinemia or Gilbert's syndrome

2. Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate
aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if subject has liver metastases).
if alkaline phosphatase is > 3 × ULN (in absence of liver metastases) or > 5 ×
ULN (in presence of liver metastases) AND the subject also is known to have bone
metastases, the liver-specific alkaline phosphatase must be separated from the
total and used to assess the liver function instead of total alkaline
phosphatase

15. Males or females age ≥ 18 years at the time of informed consent

16. All females must have a negative serum or urine pregnancy test. Females of
childbearing potential and male subjects who are partners of women of childbearing
potential must use or their partners must use a highly effective method of
contraception

17. Voluntary provision of written informed consent and the willingness and ability to
comply with all aspects of the protocol

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

EXCLUSION

1. Anaplastic or Medullary carcinoma of the thyroid

2. Two or more prior VEGF / VEGFR-targeted therapies or any ongoing treatment for
131I-refractory DTC other than TSH-suppressive thyroid hormone therapy

3. Prior treatment with lenvatinib (E7080)

4. Subjects who have received any anti-cancer treatment within 21 days or any
investigational agent within 30 days prior to the first dose of study drug and should
have recovered from any toxicity related to previous anti-cancer treatment. This
does not apply to the use of TSH-suppressive thyroid hormone therapy

5. Major surgery within 3 weeks prior to the first dose of study drug

6. Subjects having > 1+ proteinuria on urine dipstick testing will undergo 24h urine
collection for quantitative assessment of proteinuria. Subjects with urine protein ≥
1 g/24h will be ineligible

7. Gastrointestinal malabsorption, or any other condition in the opinion of the
investigator that might affect the absorption of lenvatinib (E7080). Significant
cardiovascular impairment: history of congestive heart failure greater than New York
Heart Association (NYHA) Class II, unstable angina; myocardial infarction or stroke
within 6 months of the first dose of study drug, or cardiac arrhythmia requiring
medical treatment

9. Prolongation of QTc interval to > 480 msec 10. Bleeding or thrombotic disorders or use
of anticoagulants, such as warfarin, or similar agents requiring therapeutic international
normalized ration (INR) monitoring. (Treatment with low molecular weight heparin (LMWH)
is allowed) 11. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3
weeks prior to the first dose of study drug 12. Active infection (any infection requiring
treatment) 13. Active malignancy (except for differentiated thyroid carcinoma, or
definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or
carcinoma in-situ of the cervix) within the past 24 months 14. Known intolerance to any of
the study drugs (or any of the excipients) 15. Any medical or other condition which, in
the opinion of the investigator, would preclude participation in a clinical trial 16.
Females who are pregnant or breastfeeding

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Eisai Inc.
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Eisai Inc.
    • Eisa Inc 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Eisai Inc.
    • Eisa Inc 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   3
  •   2013/12/01
* This entry means the parameter is not applicable or has not been set.